reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
HBI HANESBRANDS INC.
ESE ESCO TECHNOLOGIES INC.
DGX QUEST DIAGNOSTICS INCORPORATED
DAR DARLING INGREDIENTS INC.
FLR FLUOR CORPORATION
HWBK HAWTHORN BANCSHARES
CENX CENTURY ALUMINUM COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
WEYS WEYCO GROUP INC.
PNRG PRIMEENERGY RESOURCES
TPB TURNING POINT BRANDS
SENEA SENECA FOODS CORP. CL A
AA ALCOA CORPORATION
LMB LIMBACH HOLDINGS
SRTS SENSUS HEALTHCARE
ATGE ADTALEM GLOBAL EDUCATION INC.
DESP DESPEGAR.COM CORP.
SMID SMITH MIDLAND
FGBI FIRST GUARANTY BANCSHARES
NVST ENVISTA HOLDINGS
AFRM AFFIRM HOLDINGS
SPNT SIRIUSPOINT LTD
LMND LEMONADE INC
PAY PAYMENTUS HLDGS INC
COIN COINBASE GLOBAL INC
RKLB ROCKET LAB USA INC
PPTA PERPETUA RESOURCES CORP
ROOT ROOT INC
LUNR INTUITIVE MACHINES INC
HIPO HIPPO HLDGS INC
BG BUNGE LIMITED
LB LANDBRIDGE COMPANY LLC
FOA FINANCE OF AMERICA COMPANIES INC.
HOYFY HUHTAMAKI (VAN LEER) OYJ ADR 144A
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and...
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin (FXN) levels in study participants with Friedreich’s ataxia (FA)Modeling and simulation predict that, in most patients with FA, 50 mg of nomlabofusp administered daily is likely to achieve FXN levels that are ≥50% of levels observed in healthy controls and similar to mean FXN levels reported in asymptomatic heterozygous carriers ...
- Dylan Shindler
- Laura Chico
Velocity One Signs Merger Agreement with EMCORE (EMKR)
Velocity One Signs Merger Agreement with EMCORE (EMKR) Transaction will unite industry leaders to create an emerging force in the aerospace and defense industry FAIRFIELD, New Jersey, Nov. 08, 2024 (GLOBE NEWSWIRE) -- , a newly formed aerospace manufacturing holding company, announced today it has signed a merger agreement with EMCORE Corporation (Nasdaq: EMKR) (“EMCORE”), a provider of inertial navigation solutions to the aerospace and defense industry. Under the agreement, EMCORE will become a wholly owned subsidiary of Velocity One. The purchase price of $3.10 per share in cash, back...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TXRH TEXAS ROADHOUSE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PZZA PAPA JOHN'S INTERNATIONAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
CMRX CHIMERIX INC
CAKE CHEESECAKE FACTORY INCORPORATED
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
BJRI BJ'S RESTAURANTS INC.
CFR CULLEN/FROST BANKERS INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
DRI DARDEN RESTAURANTS INC.
EA ELECTRONIC ARTS INC.
ALBO ALBIREO PHARMA
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
ITOS ADICET BIO INC
ZNTL ITEOS THERAPEUTICS
LRMR ZENTALIS PHARMACEUTICALS
PRAX LARIMAR THERAPEUTICS INC
TVTX PRAXIS PRECISION MEDICINES
DFH TRAVERE THERAPEUTICS INC
VRDN DREAM FINDERS HOMES
RBLX VIRIDIAN THERAPEUTICS INC
DAWN ROBLOX
ELEV DAY ONE BIOPHARMACEUTICALS INC
OMGA ELEVATION ONCOLOGY
LBPH OMEGA THERAPEUTICS
STX LONGBOARD PHARMACEUTICALS
ATXS SEAGATE TECHNOLOGY HLDGS PLC
AVTE ASTRIA THERAPEUTICS INC
GFS AEROVATE THERAPEUTICS INC
VIGL GLOBALFOUNDRIES INC
TYRA VIGIL NEUROSCIENCE INC
TOST TYRA BIOSCIENCES INC
EWTX TOAST INC
BROS EDGEWISE THERAPEUTICS INC
CAVA DUTCH BROS INC
APGE CAVA GROUP INC
APOGEE THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
Hawthorn Bancshares Reports Third Quarter 2024 Results
Hawthorn Bancshares Reports Third Quarter 2024 Results JEFFERSON CITY, Mo., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK), (the “Company”), the bank holding company for Hawthorn Bank, reported third quarter 2024 net income of $4.6 million, or earnings per diluted share (“EPS”) of $0.66. Third Quarter 2024 Results Net income improved $2.0 million, or 77%, from the third quarter 2023 (the "prior year quarter")EPS of $0.66, an improvement of $0.30 per share, or 83%, from the prior year quarterNet interest margin, fully taxable equivalent ("FTE") improved in the...
Hawthorn Bancshares Announces Cash Dividend
Hawthorn Bancshares Announces Cash Dividend JEFFERSON CITY, Mo., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced today that its Board of Directors approved a quarterly cash dividend of $0.19 per common share, payable January 1, 2025 to shareholders of record at the close of business on December 15, 2024. About Hawthorn Bancshares, Inc. Hawthorn Bancshares, Inc., a financial-bank holding company headquartered in Jefferson City, Missouri, is the parent company of Hawthorn Bank, which has served families and businesses for more than 150 years. Hawthorn ...
- Laura Chico
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financia...
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich’s ataxia (FA) receiving 25 mg of nomlabofusp daily for 30-180 days in ongoing open label extension (OLE) studyInitiation of PK run-in study in adolescents on track by year-end 2024Initiation of global confirmatory/registration study planned mid-2025Biologics License Application (BLA) submission for nomlabofusp targe...
- Wedbush Research
EXPE EXPEDIA GROUP INC.
BZH BEAZER HOMES USA INC.
BLDR BUILDERS FIRSTSOURCE INC.
BKNG BOOKING HOLDINGS INC.
RCUS ARCUS BIOSCIENCES
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
LEGH LEGACY HOUSING CORP
LRMR LARIMAR THERAPEUTICS INC
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
UFPI UFP INDUSTRIES INC.
YOU CLEAR SECURE INC
- Laura Chico
Emcore Corporation Confirms Receipt of Unsolicited, Non-Binding Propos...
Emcore Corporation Confirms Receipt of Unsolicited, Non-Binding Proposal from Mobix Labs, Inc. BUDD LAKE, NJ, Oct. 01, 2024 (GLOBE NEWSWIRE) -- EMCORE Corporation (Nasdaq: EMKR) (“Emcore” or the “Company), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, today confirmed that it has received an unsolicited, non-binding proposal from Mobix Labs, Inc. (“Mobix”) to acquire all of the Company’s outstanding shares for $3.80 per share in cash. The Company’s Board of Directors continues to evaluate a range of strategic and financi...
Larimar Therapeutics Announces Three Poster Presentations at the Upcom...
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at the annual being held November 12-15, 2024 in London, U.K. Nomlabofusp is a novel protein replace...
Bob Regnier Joins the Board of Directors of Each of Hawthorn Bank and ...
Bob Regnier Joins the Board of Directors of Each of Hawthorn Bank and Hawthorn Bancshares, Inc. Underscoring Their Commitment to Community Banking JEFFERSON CITY, Mo., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bob Regnier will join the Board of Directors of each of Hawthorn Bank, and its parent company Hawthorn Bancshares, Inc., (Nasdaq: HWBK), as an advisory member. In addition to his contributions on the boards, Regnier will have an active role in providing strategic advice and extending Hawthorn Bank’s reach, influence, and relationship-driven community banking model within the Kansas City m...
Larimar Therapeutics to Participate in Upcoming Investor Conferences
Larimar Therapeutics to Participate in Upcoming Investor Conferences BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in 1x1 investor meetings at the Wells Fargo Healthcare Conference, taking place September 4-6, 2024 in Boston, MA and the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY. About Larim...
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financi...
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food and Drug Administration (FDA) to participate in Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program for nomlabofusp Joined TRACK-FA Neuroimaging Consortium as an industry partner; TRACK-FA collects natural history data to establish disease-specific neuroimaging biomarkers for potential use in clinical trialsPlanning initiation of pharmacokinetic (PK) run-...
EMCORE Reports Fiscal 2024 Third Quarter Results
EMCORE Reports Fiscal 2024 Third Quarter Results BUDD LAKE, NJ, Aug. 06, 2024 (GLOBE NEWSWIRE) -- EMCORE Corporation (Nasdaq: EMKR), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, today announced results for the fiscal 2024 third quarter (3Q24) ended June 30, 2024. Management will host a conference call to discuss 3Q24 financial and business results on August 7, 2024 at 8:00 a.m. Eastern Time (ET). “Revenue came in strong at $20.4 million for 3Q24, driven by record high shipments from our Concord site and a solid performan...
EMCORE Corporation to Host Fiscal 2024 Third Quarter Conference Call o...
EMCORE Corporation to Host Fiscal 2024 Third Quarter Conference Call on August 7, 2024 BUDD LAKE, NJ, July 31, 2024 (GLOBE NEWSWIRE) -- EMCORE Corporation (Nasdaq: EMKR), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, will announce its fiscal 2024 third-quarter results for the period ended June 30, 2024, on Tuesday, August 6, 2024, after the market close. Conference Call and Webcast Information The Company will host a conference call to discuss the results at 8:00 a.m. (ET) on Wednesday, August 7, 2024. Interim Chief ...
Hawthorn Bancshares Reports Second Quarter 2024 Results
Hawthorn Bancshares Reports Second Quarter 2024 Results JEFFERSON CITY, Mo., July 30, 2024 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK), (the “Company”), the bank holding company for Hawthorn Bank, reported second quarter 2024 net income of $4.6 million and earnings per diluted share (“EPS”) of $0.66. Second Quarter 2024 Results Net income improved $0.2 million and EPS improved $0.03 per share from the first quarter 2024 (the "prior quarter”)Net interest margin, fully taxable equivalent ("FTE") of 3.33%Return on average assets and equity of 1.02% and 13.75%, respecti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.